ARTICLE | Product Development
Department of Defense scraps $20 million VaxSyn trial
January 31, 1994 8:00 AM UTC
Department of Defense scraps $20 million VaxSyn trial
WASHINGTON -- The Department of Defense has decided to scrap a planned $20 million Phase III clinical trial of MicroGeneSys Inc.'s VaxSyn (gp160) AIDS vaccine, and instead use the money to fund a vaccine therapy development program...